U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H19O5S.Na
Molecular Weight 370.395
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM EQUILIN SULFATE

SMILES

[Na+].[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])C2=CCC4=C3C=CC(OS([O-])(=O)=O)=C4

InChI

InChIKey=QTTMOCOWZLSYSV-QWAPEVOJSA-M
InChI=1S/C18H20O5S.Na/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;/h3-5,10,14,16H,2,6-9H2,1H3,(H,20,21,22);/q;+1/p-1/t14-,16+,18+;/m1./s1

HIDE SMILES / InChI
Equilin sulfate is one of the main component, which is responsible for the pharmacological action of the PREMARIN, conjugated estrogens tablets. Premarin is used to treat the moderate to severe vasomotor symptoms, vulvar and vaginal atrophy due to menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure; to treat breast cancer and advanced androgen-dependent carcinoma of the prostate (for Palliation Only). In addition, premarin is used to prevent postmenopausal osteoporosis. Equilin sulfate is a prodrug, which is hydrolyzed to the corresponding free estrogen equilin, an inhibitor of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). Human 17beta-HSD1 catalyzes the reduction of inactive estrone (E1) to the active 17beta-estradiol in breast tissues, is a key enzyme responsible for elevated levels of E2 in breast tumor tissues. Thus equilin reduce the E2 levels in breast tissues and hence the reduce risk of estrogen-dependent breast cancer.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PREMARIN

Approved Use

1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis.
Primary
PREMARIN

Approved Use

1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis.
Primary
PREMARIN

Approved Use

1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis.
Primary
PREMARIN

Approved Use

1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis.
Preventing
PREMARIN

Approved Use

1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure 1.4 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease 1.5 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) 1.6 Prevention of Postmenopausal Osteoporosis.
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In order to determine the relative potency of equilin sulfate (EqS) 15 women received oral doses of EqS (0.15, 0.31, and 0.625 mg) for 25 days. Doses of 0.31 and 0.625 mg significantly stimulated hepatic globulins. This stimulatory effect ranged from being 1.5 to 8 times greater than the effects of comparable doses of estrone sulfate and conjugated equine estrogens.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
SODIUM EQUILIN SULFATE
Common Name English
Equilin sulfate sodium [WHO-DD]
Common Name English
SODIUM EQUILIN SULPHATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2293
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
Code System Code Type Description
EVMPD
SUB13695MIG
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
SMS_ID
100000086283
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
FDA UNII
7XY8FW3E68
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
NCI_THESAURUS
C61941
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
WIKIPEDIA
Sodium equilin sulfate
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
PUBCHEM
23676225
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
EPA CompTox
DTXSID00872961
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
ECHA (EC/EINECS)
240-727-2
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY
CAS
16680-47-0
Created by admin on Fri Dec 15 15:48:59 GMT 2023 , Edited by admin on Fri Dec 15 15:48:59 GMT 2023
PRIMARY